regSNPs-splicing: a tool for prioritizing synonymous single-nucleotide substitution by Zhang, Xinjun et al.
1 3
Hum Genet
DOI 10.1007/s00439-017-1783-x
ORIGINAL INVESTIGATION
regSNPs‑splicing: a tool for prioritizing synonymous 
single‑nucleotide substitution
Xinjun Zhang1,2 · Meng Li2,3 · Hai Lin2,4 · Xi Rao2 · Weixing Feng3 · Yuedong Yang5 · 
Matthew Mort6 · David N. Cooper6 · Yue Wang7 · Yadong Wang8 · Clark Wells9 · 
Yaoqi Zhou10 · Yunlong Liu2,7,11 
Received: 30 August 2016 / Accepted: 27 February 2017 
© The Author(s) 2017. This article is an open access publication
computational algorithm to prioritize sSNVs based on their 
impact on mRNA splicing and protein function. In addition 
to genomic features that potentially affect splicing regula-
tion, our proposed algorithm also includes dozens struc-
tural features that characterize the functions of alternatively 
spliced exons on protein function. Our systematical evalua-
tion on thousands of sSNVs suggests that several structural 
features, including intrinsic disorder protein scores, solvent 
accessible surface areas, protein secondary structures, and 
known and predicted protein family domains, show sig-
nificant differences between disease-causing and neutral 
sSNVs. Our result suggests that the protein structure fea-
tures offer an added dimension of information while distin-
guishing disease-causing and neutral synonymous variants. 
Abstract While synonymous single-nucleotide variants 
(sSNVs) have largely been unstudied, since they do not 
alter protein sequence, mounting evidence suggests that 
they may affect RNA conformation, splicing, and the stabil-
ity of nascent-mRNAs to promote various diseases. Accu-
rately prioritizing deleterious sSNVs from a pool of neu-
tral ones can significantly improve our ability of selecting 
functional genetic variants identified from various genome-
sequencing projects, and, therefore, advance our under-
standing of disease etiology. In this study, we develop a 
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The inclusion of structural features increases the predictive 
accuracy for functional sSNV prioritization.
Introduction
While single-nucleotide variants (SNVs) underlie a myr-
iad of diseases, synonymous SNVs (sSNVs) that do not 
alter which amino acid is encoded have traditionally been 
assumed to have little or no biological impact. However, 
recent work suggests that sSNVs may contribute to dis-
ease pathogenesis by affecting the affinity of RNA-binding 
proteins to disrupt RNA processing and/or translational 
control (Wan et al. 2014). The importance of synonymous 
point mutations in cancer has been further demonstrated 
by a recent survey based on roughly 4000 cancer exomes 
from 19 cancer types, which showed a significant enrich-
ment of synonymous mutations in oncogenes, as compared 
to non-cancer genes with matched genomic features (Supek 
et al. 2014; Li et al. 2016; Xiong et al. 2015; Cartegni et al. 
2002; Sauna and Kimchi-Sarfaty 2011; Duan et al. 2003; 
Macaya et al. 2009; Chamary and Hurst 2005).
Current bioinformatics tools in prioritizing deleterious 
sSNVs mainly focus on the potential impacts of individual 
variants on splicing outcome. Such methods often derive a 
series of genomic features describing how a candidate vari-
ant can potentially affect splicing regulation, and attempt 
to use these features to predict either disease relevance, 
or splicing outcome, as measured by large-scale RNA-seq 
experiments. Despite the positive prediction power in pri-
oritizing disease-causing sSNVs, such methods, however, 
do not consider whether the affected splicing events will 
result in major protein function changes (Mort et al. 2014). 
As demonstrated in our previous analysis on non-frame 
shifting micro-insertions/deletions (INDELs), inclusion or 
exclusion of a stretch amino-acid sequences does not guar-
antee the functional changes of affected protein, unless they 
occur within key structural elements of the protein (Zhao 
et al. 2013). In addition, recent surveys also suggest that 
many splicing variations are crucial to the protein functions 
and organismal phenotypes (Xiong et al. 2015; Kelemen 
et al. 2013; Rivas et al. 2015; Zheng and Black 2013; Faus-
tino and Cooper 2003).
In this study, we hypothesize that considering the exon-
specific protein structure features will significantly increase 
the accuracy of the prediction. Using potential disease-
causing and neutral data sets derived from the human gene 
mutation database (HGMD), ClinVar, and 1000 Genomes 
projects, we systematically evaluated hundreds of genom-
ics and protein structure features that are associated to indi-
vidual synonymous SNVs. Our results suggest that includ-
ing protein structure features dramatically increases our 
ability for identifying disease-causing synonymous SNVs.
Results
Training data set
We constructed a training data set that includes both dis-
ease-causing and neutral sSNVs. The disease-causing 
sSNVs were selected from the human gene mutation data-
base (HGMD) (Stenson et al. 2014), and the neutral sSNVs 
were selected from the 1000 Genomes database (Genomes 
Project C et al. 2012). As of September 2014, the HGMD 
database contains 1111 deleterious synonymous mutations 
that affect splicing, of which 697 locate on the splice sites 
(+1/+2/+3 loci in donor site and −1 locus in acceptor 
site), and 414 reside inside the exon but off the splice sites. 
These two types of sSNVs are referred as variants on splice 
site consensus (VSS) and variants in internal exons (VIE), 
respectively.
Most of the variants in our training data set are in the 
DM (disease-causing) category with direct evidence of 
being disease-causing mutations. Specifically, out of 
697 VSS HGMD variants, 656 (94.1%) are in the DM 
(disease-causing) category, and out of 414 VIE HGMD 
variants, 344 (83.1%) are from DM (disease-causing) 
category. The overall distribution of categories is shown 
in Fig. S1. Since these two types of variants may affect 
splicing regulation with different mechanisms, with VSS 
variants more likely to directly interfere with the forma-
tion of the splicesome, while VIE variants playing more 
roles in affecting RNA-binding protein (RBP) binding, 
their impacts on splicing regulation were evaluated sepa-
rately. To avoid inflating the over-representation of cer-
tain genomic features due to the occurrences of multiple 
variants in the same affected exon, we randomly select 
only one variant per exon in the further analysis. This 
process results in a total of 980 deleterious sSNVs in 
the HGMD database, of which 651 and 329 locate on 
and off splice sites, respectively. Similar as our earlier 
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study on INDELs (Zhang et al. 2014), the neutral sSNVs 
were selected from the 1000 Genomes Project, in which 
genotyped individuals did not exhibit any apparent dis-
ease phenotypes. The 1000 Genomes data contain 2582 
VSS and 66,900 VIE variants, respectively. To minimize 
false positives in the neutral group of the training set, 
we only selected those sSNVs with a minor allele fre-
quency (MAF) greater than a threshold (3% for VSS and 
10% for VIE variants). The overall gold standard data 
set includes 651 disease-causing and 399 neutral VSS 
variants, and 329 disease-causing and 7231 neutral VIE 
variants, respectively. To make a balanced training set, 
we randomly selected the same number of negative data 
set as positive data set to train and test our models. To 
evaluate features that are associated with disease-caus-
ing and neutral sSNVs, and build computational model 
for novel variant prioritization, we used 2/3 of our data 
set as training data, and the remaining 1/3 as independ-
ent test data.
Disease‑causing variants tend to impact splicing 
regulation
We evaluated a broad array of features that can be classi-
fied into three major categories: genomic features charac-
terizing how individual sSNVs affect splicing regulation, 
the structural features evaluating how the inclusion/exclu-
sion of alternatively spliced exons affect protein function, 
and others (such as conservation). A detailed list of fea-
tures and how they are derived can be found in the sup-
plementary materials and online methods. As reported in 
the previous studies, features characterizing how sSNVs 
affect splicing regulation play important roles in distin-
guishing disease-causing and neutral variants (Barash 
et al. 2010). For instance, among the 201 RNA-binding 
proteins (RBPs) with known position weight matri-
ces (PWMs) (Ray et al. 2013), disease-causing sSNVs 
showed greater alteration on RBP binding in terms of 
specific diseases, comparing with neutral variants (Fig. 
S2). This is consistent on both the magnitude of match-
ing score changes, and the probability that an sSNV 
changes RBP binding (detailed calculation methods can 
be found in online methods, Fig. S3). Similarly, other 
features associated with individual variants, such as the 
RNA secondary structure features on the variant loci, the 
inherent strength of 5′- and 3′-splicing sites of exons con-
taining candidate variant, the distance between the vari-
ant loci and splicing junction, and the ability of the vari-
ants disrupting the cluster of exonic splicing enhancers 
and silencers, all have statistically significant prediction 
power for distinguishing disease-causing and neutral vari-
ants, as evaluated by the Matthew’s correlation coefficient 
(MCC), and Kolmogorov–Smirnov (K–S) test (Supple-
ment Table 1; Fig. S4).
Disease‑causing variants tend to locate within the exons 
of key structural regions
In addition to the genomic features related to splicing regu-
lation, we have observed strong prediction power for the 
measurements characterizing the protein structure features 
of the exons containing the putative variants. Disease-caus-
ing sSNVs tend to locate in the exons with lower average 
solvent accessible surface areas (ASA), indicating that they 
are more likely to be in buried core protein regions (K–S 
test p value = 2.6 × 10−7, Fig. 1a, b, Fig. S5). In addi-
tion, comparing to neutral variants, disease-causing ones 
are also under-represented in the exons in intrinsic disor-
der regions (K–S test p value = 7.0 × 10−10, Fig. 1c, d, 
Fig. S6), suggesting that they are more likely to be in the 
structural regions. Consistent with these observations, 
disease-causing variants tend to reside in the exons with 
higher percentage of overlapping with known or predicted 
protein family domains (K–S test p value = 5.9 × 10−6, 
Fig. 1g, h, Fig. S7). As for the protein secondary structures, 
exons containing disease-causing sSNVs are enriched for 
alpha-helix (K–S test p value = 0.004), and random coil 
(K–S test, p value = 0.001) (Fig. 1e, f, Fig. S8). All these 
observations strongly suggest that, in addition to features 
related to splicing regulation, protein structure features on 
the variant-containing exons can provide additional layer of 
information in distinguishing disease-causing and neutral 
variants.
Prioritizing sSNVs based on their impact of splicing 
regulation and protein structure
Based on the aforementioned evaluation, a random forest 
algorithm was employed for building a prediction model 
for distinguishing disease-causing and neutral sSNVs. We 
evaluated the model prediction using an independent test 
data set that is not used in model training. The test data 
sets for on- and off-splicing site sSNVs include 232 and 
100 pairs of disease-causing and neutral sSNVs, respec-
tively. For VSS variants (on-splicing site variants), the 
MCC and AUC values using the whole feature set were 
0.67 and 0.91, respectively. For VIE variants (off-splicing 
site variants), the MCC and AUC values were 0.47 and 
0.82, respectively. To compare our algorithm with avail-
able tools focusing only on the effects of sSNVs on splicing 
outcome, but not on the structural features of alternatively 
spliced exons, we applied SPANR (Splicing-based Analysis 
of Variants), a tool for evaluating how SNVs cause splic-
ing mis-regulation, on our independent test data set (Xiong 
et al. 2015). We also compared with a previously published 
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tool mutPred Splice (Mort et al. 2014). In our study, we 
used the maximum mutation-induced change in PSI across 
16 tissues which is reported by SPANR by default. In addi-
tion, we used the general score reported by mutPred as 
an indicator of disease-causing probability. In both cases 
(on- and off-splicing sites), our algorithm significantly 
out-performed SPANR and mutPred Splice in distinguish-
ing disease-causing and neutral variants (Fig. 2). The areas 
under curve (AUCs) for regSNPs-splicing and SPANR are 
0.91 and 0.68 for VSS variants, and 0.82 and 0.67 for VIE 
variants, respectively. In addition, mutPred Splice has AUC 
as 0.65 for VSS variants and 0.59 for VIE variants. We have 
also tested our algorithm on the pathogenic and benign 
synonymous SNVs documented in the ClinVar database. 
For VSS variants, similar to the test in our independent 
test data set, regSNPs-splicing demonstrated significantly 
improved performance than SPANR; AUCs for these two 
algorithms are 0.85 and 0.73, respectively. For the variants 
that are not on the splice site (VIE variants), however, the 
performances of the two algorithms are similar (AUCs for 
regSNPs and SPANR are 0.70 and 0.68, respectively). One 
possible explanation for this is that most benign sSNVs 
in the ClinVar database do not change splicing outcome; 
based on SPANR prediction, among 3703 benign sSNVs, 
only 3 (0.08%) can cause more than 20% change of splic-
ing inclusion (|dPSI| ≥0.2). Based on the rationale of the 
model design, regSNPs-splicing works more effective if the 
pathogenic variants contain substantial amount of variants 
that do cause splicing change, while the resultant splicing 
change does not cause protein function changes.
Minor allele frequency is reversely correlated 
with disease‑causing probability
We obtained allele frequencies for all the synonymous 
variants from the 1000 Genomes Project data. The allele 
frequency in the population should, in general, reflect the 
occurrences of that allele with respect to its putative bio-
logical function. As expected, there was a strong nega-
tive correlation between the predicted disease-causing 
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Fig. 1  Cumulative probability density function (CDF) curves and 
Kolmogorov–Smirnov (K–S) test p values on various protein struc-
ture features for the exons containing disease-causing (red) and neu-
tral (black) sSNVs. a CDF of the average solvent accessible surface 
area (ASA) of all the amino-acid residuals in the exon. b KS–S test 
p values for the average, minimum and maximum ASA values of all 
the amino-acid residuals in the exon. c CDF of the average disorder 
score of all the residuals in the affected exon. d K–S test p values 
for 12 disorder score-derived features (Supplementary Table 1). e 
CDF of the average probability of the most likely protein secondary 
structure (alpha-helix, beta sheet, or random coil) on all the residu-
als in the affected exon. f K–S test p value for 12 protein secondary 
structure-derived features (Supplementary Table 1). g, h CDF and 
K–S p values of the percentage of the exon overlapping with known/
predicted Pfam domain. i, j CDF and K–S p values of the normalized 
PTM counts in the affected exon
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probability and allele frequency for both VSS and VIE vari-
ants with correlation coefficient = 0.32 and 0.88, respec-
tively (Fig. 3a, b).
Web‑based analysis portal
We provide a Web access to our tool (http://watson.com-
pbio.iupui.edu/regSNP-splicing/) and also a download link 
of the source code and database annotation files.
Discussion
The genetic code error arising from a single silent nucle-
otide variation can be populated through transcriptional 
regulation, post-transcriptional regulation, and translation 
process. The mis-splicing of exon in mRNA eventually 
will change protein structure and affect protein’s func-
tion. Many disease phenotypes can be traced back to that 
“nucleotide switch” which triggered dramatic alteration 
of biological processes (Milenkovic et al. 2010; Akiyama 
et al. 2007; Neveling et al. 2012; Banerjee et al. 2011; 
Leontiou et al. 2008). To elucidate the subsequent abnor-
mal biological process which are implemented with aber-
rant genetic information, several studies have investigated 
the genetic context of nucleotide sequence around sSNV 
and further extend to a comprehensive profile of affected 
splicing regulation elements (Kurmangaliyev and Gelfand 
2008; Ward and Cooper 2010; Baralle and Baralle 2005). 
Despite of these efforts, the examination of protein func-
tion and structural integrity is largely dismissed yet provid-
ing a direct interpretation of disease mechanism. In addi-
tion to the genomic sequence including length of exon and 
intron, proximity to exon boundary, conservation, exon 
junction site strength, and splicing regulation motifs, we 
extend our scope to protein structure and function features: 
(a) (b)
(c) (d)
Fig. 2  Comparison between regSNP-splicing and SPANR on inde-
pendent test variant data set and ClinVar variant data set. a, b ROC 
curves showing the performance of regSNP-splicing (red curve) and 
SPARN (blue curve) on an independent test data sets for VSS, and 
VIE variants, respectively. c, d ROC curves showing the performance 
of regSNP-splicing (red curve), SPARN (blue curve) and mutPred 
Splice (black curve) for VSS and VIE variants documented in the 
ClinVar database, respectively
Fig. 3  Reverse correlation between average minor allele frequency 
(MAF) and average predicted disease-causing probability for a on-
splicing site and b off-splicing site 1000 Genomes variants, respec-
tively. Minor allele frequency, ranging between 0 and 1, is divided 
into 20 equal bins, and each bin represents 0.05 increment of MAF. 
For all the variants with MAF falling into each bin, we calculated 
their average MAF and average disease-causing probability values. 
One dot represents a pair of average MAF and average DCP. A linear 
model was fitted for the 20 dots and R2 value is calculated
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solvent accessible surface area, protein secondary structure, 
intrinsic disorder score, Pfam domains, and post-translation 
modification sites. Our analyses confirmed the conclusions 
from the previous studies (Scott et al. 2012; Ward and Kel-
lis 2012; Pagani et al. 2005; Woolfe et al. 2010) that synon-
ymous SNVs can have great influence on the splicing regu-
lation. We have observed significant differences on a broad 
array of genomic features that are associated with disease-
causing and neutral sSNVs, respectively. Importantly, our 
results strongly suggest that the protein structure features 
offer an added dimension of information while distinguish-
ing disease-causing and neutral synonymous variants. The 
inclusion of structural features increases the predictive 
accuracy for functional sSNV prioritization.
In our research, we specifically split our data set into two 
parts: one set of sSNVs defined as “on consensus splicing 
site” and it contains sSNVs which are very close (within 3 
nucleotides to donor site or one nucleotide to acceptor site). 
In addition, the other set of sSNVs are defined as “variants 
in internal exon” which contains sSNVs that are >3 nucleo-
tides from donor site and >1 nucleotide from acceptor site. 
For the data set “on consensus splicing site”, we did not 
use the proximity to exon boundary as a feature for model 
training, since it is a very strong indicator to distinguish 
whether a synonymous mutation is disease-causing or neu-
tral. Therefore, our model for the variant on splicing site 
does not learn the position of sSNVs. For the data set “in 
internal exon”, we examined the proximity from the loca-
tion of sSNV to the closer splicing junctions and we can 
tell that proximity is a useful feature but not overwhelm-
ing (plot h, Fig. S4). Therefore, for the data set “in interval 
exon”, our model does not just learn the position of sSNV 
either.
To evaluate the performance of our tool in predicting 
disease-causing mutations, we have compared our tool with 
SPANR and mutPred Splice (Mort et al. 2014). SPANR 
and mutPred Splice were primarily designed to quantify 
splicing level change of one exon in the presence of single-
nucleotide variation. Although SPANR and mutPred Splice 
do not have a specific disease focus, the splicing level 
change is a strong indicator of disease relevance (Ward and 
Cooper 2010). Therefore, both tools are capable of predict-
ing disease-causing mutations based on same rationale.
As a direct evaluation of the importance of protein fea-
ture, we evaluated the power of protein level information 
separately. We divided all the features into three catego-
ries: DNA evolution, splicing regulation features, and pro-
tein function and structure features. For every category, we 
trained and tested one single model based on tenfold cross 
validation. For the model built using nucleotide evolution, 
we plotted ROC curve, and the AUC is 0.56 for VSS vari-
ants and 0.59 for VIE variants. For the model built using 
splicing regulation features, the AUC is 0.91 for VSS 
variants and 0.81 for VIE variants. For the model built 
using protein features, the AUC is 0.67 for VSS variants 
and 0.71 for VIE variants. Therefore, for both VIE and VSS 
variants, protein function and structure features have been 
demonstrated of strong classification power (Fig. S9).
To make our model independent of gene, we have 
strictly controlled sequence similarity in our model train-
ing and testing process. In the original HGMD and 1000 
Genomes Project data set, there are scenarios that multi-
ple variants originate from the same exon. To avoid over-
representation of such exons and genes in our models, we 
kept only one variant per exon in both training and test-
ing data. Furthermore, we performed a more strict control 
of sequence similarity in our training and testing data set. 
For each gene family, we only selected the gene with most 
number of exons and then we only keep variants in this 
gene. And then, we trained our models using the remaining 
data. Using tenfold cross-validation strategy, the model for 
VSS has achieved AUC as 0.93 and the model for VIE has 
AUC as 0.84 (Fig. S10). We demonstrated that our models 
were not significantly affected by sequence similarity.
In our current model, the structural information on the 
potential disease-causing isoform is not calculated. The 
first reason is that we believe that evaluating the structural 
information on the naturally occurring splicing events has 
provided enough sensitivity to our approach. In addition, 
more importantly, for practical purpose, calculation for 
structural information based on amino-acid sequences is 
very time-consuming. To make the tool usable to general 
public, most of the protein features are pre-calculate based 
on the current gene annotation.
However, our models also have some limitations. One of 
the limitations is that our training data size of HGMD is 
not large enough. This can be improved with the growth of 
the databases of HGMD and ClinVar in the future. Another 
limitation is that the protein structure features are all pre-
diction based. This is reasonable, otherwise using known 
protein structures information in PDB database will limit 
the training data set size and impose difficulty on imple-
mentation of both model training and testing. However, this 
would add another level of inaccuracy.
Methods
Training data sets
A “gold standard” data set for the development of machine 
learning-based prediction algorithms was obtained from 
the human gene mutation database (HGMD) and the 
1000 Genomes Project. The positive training set was 
acquired from the HGMD database, which contains 1373 
disease-causing synonymous SNVs (sSNVs) that have 
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experimentally been verified to cause disease through 
affecting the processes of alternative splicing. We further 
removed the variants reside in the first exon and last exon 
of a gene, whose inclusion/exclusion status is often regu-
lated through mechanisms other than splicing regulation, 
such as alternative promoter, or alternative polyadenyla-
tion. The positive and negative data sets may be biased by 
repetitively appeared genes and exons which can introduce 
highly homologous sequences into our training data sets. 
To avoid the over-representation of certain exons due to the 
occurrences of multiple disease-causing variants, we only 
keep one variant per exon. Therefore, one exon is used only 
once for training and testing purposes. The remaining 980 
disease-causing sSNVs were further classified into two 
groups, the one locating at +1/+2/+3 nucleotides on the 
donor side, and −1 nucleotide on the acceptor side is con-
sidered as on consensus splice site variants (VSS), while 
the other variants are considered as in internal exon (VIE). 
We have also removed the variants appearing in the ClinVar 
database for training purpose. This classification resulted in 
651 VSS and 329 VIE disease-causing sSNVs, respectively.
The negative training set, i.e., “neutral” synonymous 
variants, was acquired from the 1000 Genomes Project, 
in which genotyped individuals did not exhibit any appar-
ent disease phenotypes. To minimize false positives, we 
selected only those sSNVs with a minor allele frequency 
(MAF) greater than 10% for VIE variants, and 3% for 
VSS variants. The reduced MAF cutoff for VSS variants 
is implemented due to the limited available number of on 
splicing site sSNVs in the 1000 Genomes database. This 
selection criterion resulted in 7231 neutral VIE variants, 
and 329 VSS variants, respectively.
In addition to the HGMD database, the synonymous 
variants documented in the ClinVar database were used 
as test data set for model evaluation. The current ClinVar 
database contains 4765 synonymous variants, of which 
230 and 4535 are pathogenic and benign, respectively. 
To avoid potential evaluation bias due to the overlapping 
records between HGMD and ClinVar, we have removed the 
overlapping variants from the training data set. Although 
the total number of usable sSNVs in ClinVar database is 
limited, it offers the opportunity to validate the prediction 
accuracy from an independent test data set.
Feature description
We evaluated a broad array of features that can be classi-
fied into three major categories: genomic features charac-
terizing how individual SNVs affect splicing regulation, 
structural features evaluating how the inclusion/exclusion 
of alternatively spliced exons affect protein function, and 
others (such as conservation). A detailed list of features can 
be found in Supplementary Table 1.
Genomic features
Potential impacts of sSNVs on the binding affinities 
of RNA‑binding proteins (RBPs) For a given sSNV, its 
effect on the binding of a particular RBP (RNA-binding pro-
tein) will be evaluated by the differences in the RBP-binding 
scores between reference and alternative alleles. The RBP-
binding score was calculated based on the RNA sequence 
and the RBP position weight matrix (PWM) documented in 
the RBPDB and cisBP-RNA databases; collectively, these 
two databases contain the PSSMs of 201 RNA-binding pro-
teins (Ray et al. 2013; Cook et al. 2011). A PWM is a matrix 
of values that gives the count of each nucleotide at each 
locus of the binding site. The binding affinity between the 
n-nt RNA sequence, and the PWM is described by a match-
ing score S as follows:
where ni,j is the count of the jth nucleotide on the ith posi-
tion in one PWM, ci,j is the pseudocount for the jth nucleo-
tide on the ith position in the PWM, and dj is the prior base 
frequency for the jth nucleotide (dj = 0.25 for j = A, T, G, 
C). N is the total number of experimentally validated bind-
ing sites for one RBP, and k is the width of the binding site.
In Eq. (1), a high or low matching score indicates that 
the putative sequence has, respectively, a high or low like-
lihood to be a potential binding site. Each position of a 
binding site is assumed to be independent of the other. The 
matching score distributions for binding and non-binding 
events were both estimated based on PSSM of an indi-
vidual RBP. We assume that the matching score follows a 
Gaussian distribution, with mean as Ms and variance as Vs. 
The mean and variance of the binding scores for specific 
RBP-binding events are defined as follows:
In Eq. (2), the score si,j is the value of the ith col-
umn and the jth row of the position specific score matrix 
(PSSM), which is defined as the logarithmic ratio of the 
percentage of the jth nucleotide (A, C, G, or U) in col-
umn i of the binding sites to the percentage in random 
(1)S =
k∑
i=1
∑
j∈{A,T ,G,C}
log2
(nij + cij)/(N +
∑4
j=1 cij)
dj
,
(2)sij = log2
(nij + cij)/(N +
∑4
j=1 cij)
dj
,
(3)Ms =
k∑
i=1
∑
j∈(A,T ,G,C)
fij × sij,
(4)Vs =
k∑
i=1
∑
j∈{A,T ,G,C}
fij × s2ij − (fij × sij)2.
 Hum Genet
1 3
sequence. In this equation, ni,j is the count of the jth 
nucleotide on the ith position in the PWM, ci,j is the pseu-
docount for the jth nucleotide on the ith position in the 
PWM. N is the total number of experimentally validated 
binding sites for each RBP. dj is the prior base frequency 
for the jth nucleotide (dj = 0.25 for j = A, T, G, C).
In Eqs. (3) and (4), fi,j is the approximation of the true 
frequency of each nucleotide at each binding locus. For 
binding events,
and for non-binding events, fi,j = 0.25.
As defined in our previous study on transcription fac-
tors and micro-INDELs, the magnitude (M) of a sSNV 
affecting the binding of an RBP is defined as a likelihood 
ratio of the sSNV affected loci being a binding event as 
opposed to it being a non-binding event in reference and 
alternative forms, respectively:
(5)fij = 2
sij
4
,
where R and A indicates whether a genetic locus is in ref-
erence or alternative form, B means “binding event” and 
NB means “non-binding event”. Therefore, R = B means 
that the genetic locus in its reference status is a binding 
site of RBP, and vice versa. Random variables B and NB 
(7)
P = P(R = B,A = NB|SR , SA)+ P(R = NB,A = B|SR , SA)
= P(R = B,A = NB)P
(
SR , SA|R = B,A = NB
)
P
(
SR , SA
)
+ P(R = NB,A = B)P
(
SR , SA|R = NB,A = B
)
P
(
SR , SA
)
= P(R = B)P(A = NB)P(SR|R = B)P
(
SA|A = NB
)
P(SR)P
(
SA
)
+ P(R = NB)P(A = B)P(SR|R = NB)P
(
SA|A = B
)
P(SR)P
(
SA
)
= P(B)(1− P(B))[P(SR|R = B)P
(
SA|A = NB
)+ P(SR|R = NB)P(SA|A = B)]
P(SR)P(SA)
=
1
∫
0
[P(B)(1− P(B))(P(SR|R = B)P
(
SA|A = NB
)
+ P(SR|R = NB)P
(
SA|A = B
)
)/P(SR)P
(
SA
)
d(B)
(6)M = log2
P(SA|B)/P(SA|NB)
P(SR|B)/P(SR|NB)
= log2


∫SA−∞ 1√2piVS e
− 12
�
x−MS
VS
�2
d(x)/

1− ∫SA−∞ 1√2piV ′S e
− 1
2
�
x−M′
S
V
′
S
�2
d(x)


∫SR−∞ 1√2piVS e
− 12
�
x−MS
VS
�2
d(x)/

1− ∫SR−∞ 1√2piV ′S e
− 12
�
x−M′
S
V
′
S
�2
d(x)




where R and A indicates the reference and mutated sites, 
respectively; B and NB denote binding and non-binding 
events, respectively. SR and SA each represents the match-
ing scores of the reference and mutated sites. P(SA|B) is 
the probability of matching score SA of mutated site when 
it is a binding event, and P(SA|NB) is the probability of 
SA when it is a non-binding event. Similarly, P(SR|B) is 
the probability of matching score SR of reference site 
when it is a binding event and P(SR|NB) is the probability 
of matching score SR for non-binding event. MS and VS 
are, respectively, the mean and variance of the matching 
score for binding events, and M ′S and V ′S are the mean and 
variance of the matching score of non-binding events. A 
positive M score indicates a gain of an RBP-binding site, 
whereas a negative M score indicates the loss of an RBP-
binding site.
We further calculate a Bayesian-based posterior proba-
bility for RBP-binding-site gain/loss, defined as the prob-
ability that a genetic locus could switch between binding 
and non-binding status, with and without the synonymous 
variant:
are both assumed to follow beta distribution. We assume 
that R and A are independent of each other and SR and 
 SA are also independent of each other. P(B) is the prior 
probability that a genomic region is a binding site for a 
RNA-binding protein. We also assume that the distribu-
tion of random variable B has mode value as 0.05. SA 
denotes the matching score for alternative form and SR 
denotes the matching score for reference form. We inte-
grated over B to get the overall probability that one sSNV 
has changed the status of a genomic region from binding 
status to non-binding status, or from non-binding status 
to binding status.
RNA secondary structure features on the variant loci RNA-
binding protein binding has well-established preference on 
specific RNA secondary structures; some proteins tends 
to bind on single-stranded regions, others double-stranded 
regions. Such preference may provide additional specificity 
for RBP binding. In addition, single-nucleotide changes may 
disrupt the overall RNA secondary structure on the RBP-
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binding sites, and further affect RBP-binding affinity. For a 
specific sSNV, we calculated the average single-strandness 
probability for the nucleotides upstream and downstream 7 
bases of variant locus (putative-binding sites), which is cal-
culated using RNAfold (Lorenz et al. 2011). The changes 
on the RNA secondary structure caused by sSNV on the 
putative binding sites are calculated using RNAdistance 
(Lorenz et al. 2011).
Inherent strength of 5′‑ and 3′‑splicing sites of exons con‑
taining candidate sSNVs We previously reported that the 
sSNVs residing in the AS exons are more likely to have 
phenotypic consequences (Teng et al. 2011). We therefore 
evaluated the inherent strength of 5′- and 3′-splicing sites of 
exons containing candidate sSNVs. This measurement may 
serve as an important feature for quantifying whether the 
candidate splicing events require additional assistance from 
other RNA-binding proteins; more assistance from RBPs 
may be needed for an exon with weaker junction strength. 
The inherent splicing strength of 5′- and 3′-splicing sites are 
calculated based on the position weight matrices (PWMs) 
describing the sequence features on/around canonical splic-
ing sites (Itoh et al. 2004).
ESE/ESS cluster scores Exonic splicing motifs which con-
sist of 6 nucleotides within an exon are categorized as exon 
spicing enhancer (ESE) or exon splicing silencer (ESS) 
based on whether they promote or prohibit splicing process, 
respectively. We scanned the affected exons and search for 
occurrences of known or predicted ESE and ESS motifs. For 
this purpose, we have collected 76 known motifs, 2298 pre-
dicted ESE motifs, and 1195 predicted ESS motifs (Barash 
et al. 2010; Fairbrother et al. 2002; Zhang and Chasin 2004). 
Overlapping motifs are combined and further defined as a 
‘motif set’. Multiple motif sets which are located within 6 bp 
apart are defined as a ‘motif cluster’. Within a motif cluster, 
a gap ≤3 bp is denoted as a short interval—and a gap larger 
than 3 bp and less than or equal to 6 bp is denoted as a long 
interval. The total number of occurrence of short intervals is 
denoted as Is and the total count of long intervals is denoted 
as Il. Then, a motif set is scored as Sset = 2Nm−1, where 
Nm is the number of overlapping motifs. A motif cluster is 
scored based on Is, Il and number of motif sets within a motif 
cluster, where Scluster = (2 · Is + Il + #motif set)+ Sset. Sset 
is defined to measure the local density of splicing motifs 
within an exon, and Scluster is measuring the aggregation of 
motif sets. Finally, the enrichment of ESE and ESS within 
an exon using a ‘cluster score’ is defined as follows:
(8)Cluster score = log
Scluster
exon length
where exon length’s unit is per 100 base pairs. The effect of 
a specific SNV on ESE/ESS clustering is evaluated based 
on the differences of cluster scores for the reference and 
alternative alleles, respectively.
Proximity to the 5′‑ and 3′‑splicing junction The prox-
imity is defined as the distance from a variant and exon 
boundaries. Here, we separate our SNVs into two different 
categories: on splicing site (within 3 bp of donor sites or 
1 bp of acceptor site) and off-splicing site (the other regions 
of exon). SNVs on splicing site mainly interferes with vari-
ous molecular and affect formation of spliceosome, and the 
off-splicing site SNVs mainly affect the binding of splicing 
regulators. This feature is not used for on-splicing site vari-
ants.
Protein structure/function features
Disruption of protein secondary or tertiary structures is one 
possible reason for deleterious alternative splicing events. 
We, therefore, evaluated several features describing the 
effects of affected splicing pattern on protein structures. 
Such features include protein structure/intrinsic disorder 
scores, solvent accessible surface areas (ASA), protein sec-
ondary structures, and known and predicted protein family 
domains (pfam). In addition, the known post-translational 
modification status on the affected splicing event is also 
evaluated.
Intrinsic disordered regions Intrinsically disordered 
regions are defined as a stretch of amino-acid sequences that 
lack the ordered tertiary and/or secondary structures. We 
have previously reported applying disorder score of affected 
protein regions in distinguishing disease-causing and neu-
tral micro-insertion and -deletions (Zhang et al. 2014). 
Similarly, we measured the disorder property of affected 
protein regions that result from the mis-spliced exon in tran-
script. Disorder property of the affected region is quanti-
fied through calculating the disorder score of each involved 
amino acid using spine-D (Zhang et al. 2012).
Solvent accessible surface areas (ASA) Solvent accessible 
surface area has been used as an important feature for vari-
ant prioritization (Folkman et al. 2015; Zhao et al. 2013). 
Based on ASA value, an amino acid can be classified as bur-
ied inside or on the surface of a protein. To some degree, 
ASA can be used to infer the flexibility and predict bind-
ing induced structure conformational change of monomeric 
proteins (Marsh and Teichmann 2011). The ASA value for 
the affected exon is calculated using Spline-X with default 
parameters (Faraggi et al. 2009).
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Protein secondary structure The most probable second-
ary structure (alpha-helix, beta sheet, or random coil) on the 
affected exons are calculated using Spline-X (Faraggi et al. 
2009) using default parameters.
Overlapping with known or predicted protein family 
domains (Pfam) The functional regions of proteins are 
generally termed as domains. The direct consequence 
of abnormal splicing is loss or gain of one or more pro-
tein domains due to missing or addition of a fragment 
of protein sequence. The integrity of protein function is 
determined by the combination of domains and therefore 
abnormal splicing directly affects protein’s function. We 
have collected in total 86,748 high quality Pfam-A protein 
families (49,991 domains, 28,062 families, 703 Motifs, 
and 7992 repeats) from Pfam database (Finn et al. 2014). 
As a measurement of the importance of affected exon on 
protein domains, we calculated a percentage value as the 
proportion of affected protein region which overlaps with 
documented Pfam domains.
Post‑translational modification sites (PTMs) Post-trans-
lational modifications on amino acids play an important 
role determining the function and activities of a protein. To 
evaluate the potential PTM status of the exons containing 
functional sSNVs, We downloaded 372,456 experimentally 
verified PTM sites from dbPTM 3.0 database (Lu et al. 
2013). Among those PTMs, most common modifications 
are phosphorylation, ubiquitylation, and acetylation. As a 
comparison on the density of PTM sites, we calculated the 
normalized PTM site amount per 100 amino acids on the 
affected protein region.
Machine learning model
We discovered the excellent classification capability of ran-
dom forest in our previous study. In addition, in this study, 
we continued to use random forest as the tool to learn the 
distinct genomic and protein structural and functional fea-
tures between disease-causing and neutral variants. Ran-
dom forest is composed a certain number of decision trees 
and the final prediction is the polled vote of each tree’s 
prediction result. For training purpose, random forest algo-
rithm randomly selects (bootstrap) a proportion of training 
samples for growing each node. The feature for each node 
is selected from a subset of features bootstrapped from the 
total set of features, based on a certain split criterion such 
as information gain or Gini index. In our study, we used a 
software package called Weka to build our random forest 
model (Witten et al. 2016). We did not implement feature 
selection before training our model due to the bootstrap 
step in both selecting training sample and selecting features 
when building each node. We tuned the number of trees to 
grow for random forest as 51 and the number of features 
subset for building each node as 35. Two different models 
are trained independently for variants on splicing sites and 
off-splicing sites, respectively.
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